Alaunos Therapeutics (TCRT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alaunos Therapeutics, Inc. has approved a reverse stock split of its common stock at a ratio of 1-for-15, to take effect on January 31, 2024. The stock will trade on The Nasdaq Capital Market with a new CUSIP number post-split. This decision, determined by the Board of Directors with a stockholder-approved range of 1-for-5 to 1-for-15, follows the initial Board approval and subsequent stockholder endorsement at the annual meeting. Equiniti Trust Company will manage the exchange of shares for stockholders.
For further insights into TCRT stock, check out TipRanks’ Stock Analysis page.